...
首页> 外文期刊>Scientific reports. >Clinical Investigation of the Posterior scleral contraction to Treat Macular Traction Maculopathy in Highly Myopic Eyes
【24h】

Clinical Investigation of the Posterior scleral contraction to Treat Macular Traction Maculopathy in Highly Myopic Eyes

机译:后巩膜收缩治疗高度近视眼中黄斑牵引片的临床研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Myopic traction maculopathy (MTM) can cause vision disabilities in highly myopic eyes. This retrospective case series investigated the clinical outcomes of posterior scleral contraction (PSC) using genipin-cross-linked sclera as the material to treat MTM in highly myopic eyes. In total, 32 eyes from 29 highly myopic patients who underwent PSC for MTM were recruited. The changes in best-corrected visual acuity (BCVA) and axial length were evaluated, macular reattachment and macular hole (MH) closure was assessed by optical coherence tomography, and complications were evaluated. At the final follow-up, the retina was completely reattached in 25 eyes (78.1%), essentially reattached in 4 eyes (12.5%), and partially reattached in 3 eyes (9.4%). The logMAR BCVA improved significantly from 1.18?±?0.45 preoperatively to 0.87?±?0.45 postoperatively (P??0.001). The 32 eyes were further divided into the MH group (16 eyes) and the non-MH group (16 eyes) for comparison. The MH was closed in 9 eyes (56.3%). The retinal reattachment rate was 75.0% in the MH group and 81.25% in the non-MH group, and the logMAR BCVA improved significantly in both groups. The PSC using genipin-cross-linked sclera as the material can effectively treat MTM in highly myopic eyes, and significant visual improvement can be achieved with minimal complications.
机译:近视牵引力疗法(MTM)可以引起高度近视眼的视力残疾。这种回顾性案例系列研究了使用Genipin-Crons-Constled Sclera作为治疗MTM在高度近视眼中的材料的临床结果。总共招募了来自29名高度近视患者的32只眼睛招募了患有MTM的PSC。评价最佳校正的视力(BCVA)和轴向长度的变化,通过光学相干断层扫描评估黄斑重新点和黄斑孔(MH)闭合,并评估并发症。在最后的随访中,视网膜完全重新凝固25只眼睛(78.1%),基本上重新连接到4只眼睛(12.5%),并在3只眼中部分重新凝固(9.4%)。 Logmar BCVA从1.18α±±0.45显着改善至0.87?±0.45±0.45(P?<0.001)。 32只眼进一步分为MH组(16只眼)和非MH组(16只眼)进行比较。 MH在9只眼里关闭(56.3%)。在MH组中,视网膜重新连接率为75.0%,在非MH组中为81.25%,两组的Logmar BCVA显着改善。 PSC使用Genipin-Crons-Latched Sclera作为材料可以有效地治疗MTM在高度近视眼中,并且可以通过最小的并发症来实现显着的视觉改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号